﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Journal of Cardiovascular and Thoracic Research</JournalTitle>
      <Issn>2008-5117</Issn>
      <Volume>16</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month>06</Month>
        <DAY>25</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>The role of probiotics on microvascular complications of type-2 diabetes: Nephropathy and retinopathy</ArticleTitle>
    <FirstPage>65</FirstPage>
    <LastPage>76</LastPage>
    <ELocationID EIdType="doi">10.34172/jcvtr.32877</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Robab</FirstName>
        <LastName>Sarmadi</LastName>
      </Author>
      <Author>
        <FirstName>Hajie</FirstName>
        <LastName>Lotfi</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0001-8450-748X</Identifier>
      </Author>
      <Author>
        <FirstName>Mohammad Amin</FirstName>
        <LastName>Hejazi</LastName>
      </Author>
      <Author>
        <FirstName>Fariba</FirstName>
        <LastName>Ghiasi</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-8992-3033</Identifier>
      </Author>
      <Author>
        <FirstName>Rana</FirstName>
        <LastName>Keyhanmanesh</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-6941-2690</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>REVIEW</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/jcvtr.32877</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>06</Month>
        <Day>07</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>05</Month>
        <Day>04</Day>
      </PubDate>
    </History>
    <Abstract>Diabetes is a multifactorial disorder that involves several molecular mechanisms and is still one of the key global health challenges with increasing prevalence and incidence. Gut microbiome dysbiosis could activate and recognize receptors that trigger the inflammation response and modulation of insulin sensitivity. In addition, the intricate role of gut microbiota dysbiosis in the onset and development of T2D (Type 2 diabetes mellitus) and associated microvascular complications was identified. These complications include diabetic nephropathy (DN) and diabetic retinopathy (DR), diabetic neuropathy, cerebrovascular disorders, and coronary heart disease. A recent interesting strategy to improve these complications is probiotics administration. The safety and health effects of probiotics against various diseases have been validated by various in vitro, in vivo and clinical studies. In this review, the related mechanisms between the gut microbiome, initiation, and progression of T2D and its common microvascular complications (DN and DR) have been discussed.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Probiotics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gut microbiota</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Type 2 diabetes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Retinopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nephropathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Microvascular</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>